MRI, PET and µCT imaging are well-established in the study, diagnosis, and treatment of heart disease. From detection of cardiomyopathy to monitoring of atherosclerotic lesion burden, those techniques complement each other in regards to speed of use, functional and structural capabilities. Generally, all in-vivo imaging methods benefit from minimal invasiveness,
Imaging technologies have been instrumental in this field, and Bruker’s dedicated line of products will help take your studies to the next level. As opposed to Ultrasound Bruker's modalities offer true 3D tomographic imaging without penetration depth limitation in preclinical imaging applications. For those looking to identify novel pathways, potential drug targets, and treatment outcomes, Bruker’s instruments aid the identification and localization of cardiac abnormalities as well as monitoring of disease progression.
Researchers seeking to better understand cardiac disorders will be amazed by the structural and functional analysis which is possible with images from Bruker's small-animal MRI technology, which allows the non-invasive, longitudinal, detection of minute changes occurring in relation to disease progression, genetic and dietary alteration, or pharmacological intervention.